ImmunityBio (IBRX) Revenue (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Revenue data on file, last reported at $44.2 million in Q1 2026.

• On a quarterly basis, Revenue rose 167.64% year-over-year to $44.2 million in Q1 2026; TTM through Mar 2026 was $141.0 million, a 351.53% increase from a year earlier, with the FY2025 full-year figure at $113.3 million, up 668.31% from the prior year.
• Revenue for Q1 2026 stood at $44.2 million, up from $38.3 million in the prior quarter.
• Over the last five years, Revenue for IBRX reached as high as $44.2 million in Q1 2026 and fell as low as $14000.0 in Q1 2022.
• Historically, Revenue has averaged $10.2 million across 5 years, with a median of $360000.0 in 2023.
• Across the five-year window, Revenue slumped 89.93% in 2022 and surged 41192.5% in 2025, its largest moves.
• Year by year, Revenue stood at $73000.0 in 2022, then soared by 90.41% to $139000.0 in 2023, then soared by 5333.09% to $7.6 million in 2024, then soared by 406.95% to $38.3 million in 2025, then rose by 15.47% to $44.2 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $44.2 million in Q1 2026, $38.3 million in Q4 2025, and $32.1 million in Q3 2025.